Risk group-Very high risk Posts on Medivizor
Navigation Menu

Risk group-Very high risk Posts on Medivizor

17p deletion and 8q24 gain: Two chromosomal abnormalities that can predict outcomes

Posted by on Mar 11, 2018 in Leukemia | 0 comments

In a nutshell This study examined causes and outcomes of a chromosomal abnormality known as 17p deletion in chronic lymphocytic leukemia (CLL). Researchers reported poor outcomes for patients that have both 17p deletion and 8q24 gain. Some background Certain genetic changes in CLL can make it more difficult to treat. Changes in the chromosomes, such...

Read More

A review of CAR-T cell therapy for CLL

Posted by on Jan 27, 2018 in Leukemia | 0 comments

In a nutshell This study reviewed CAR-T cell therapy, a new type of immunotherapy, for chronic lymphocytic leukemia (CLL). Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In this treatment, immune cells (the T-cells) are removed from the blood. The T-cells are then genetically modified...

Read More

An analysis comparing reduced-intensity conditioning and myeloablative therapy for CLL

Posted by on Dec 30, 2017 in Leukemia | 0 comments

In a nutshell This study analyzed the results of 37 studies comparing myeloablative therapy and reduced intensity conditioning (RIC) before stem cell transplantation in patients with chronic lymphocytic leukemia (CLL). This study concluded that RIC was associated with lower mortality and better survival compared to myeloablative therapy. Some...

Read More

Long-term outcomes of allogeneic stem cell transplantations in young high-risk CLL patients

Posted by on Oct 5, 2017 in Leukemia | 0 comments

In a nutshell This study examined predictors of outcomes with stem cell transplantation from a donor (allo-SCT) for chronic lymphocytic leukemia (CLL). Researchers reported good long-term outcomes for young high-risk CLL patients treated with allo-SCT. Patients with matched sibling donors showed better outcomes compared to those with matched unrelated...

Read More

Is stem cell transplantation a viable option among AML patients who are not in remission?

Posted by on Sep 3, 2017 in Leukemia | 0 comments

In a nutshell This study examined stem cell transplant outcomes across acute myeloid leukemia (AML) patients with different disease status. Researchers reported superior survival after a stem cell transplant among patients in second complete remission.  Some background Stem cell transplantation is considered the most effective therapy for...

Read More